The Solubility Company appoints Head of Business Development for the key North American market

The Solubility Company continues its strategic US expansion with appointment of Matt Fodor as Head of Business Development, North America

The Solubility Company is set to accelerate its rapid growth and expansion into the North American market with the appointment of Matt Fodor as Head of Business Development, North America. The newly created role will expedite the expansion of The Solubility Company’s revolutionary image-based SPA® (Single Particle Analysis) technology and related services in the key North American market. The SPA® technology is designed for early-stage solubility data generation, enhancing and accelerating pharmaceutical research and development efforts.

 Matt joins The Solubility Company after having spent most of the last decade in contract manufacturing as both a process chemist and a business development executive. He holds a PhD in chemistry from the Pennsylvania State University, an MBA from the State University of New York at Albany and completed his post-doctoral training at Harvard University. Since 2019, Matt has excelled in roles of increasing commercial responsibility at Curia Global, Inc.

 “Matt is an outstanding addition to our team, as he brings a deep blend of subject expertise and what it takes to deliver client success,” says Sami Svanbäck CEO of The Solubility Company. “As The Solubility Company continues its rapid growth and strategic focus across North America, Matt’s sales leadership and his strong background within the pharmaceutical services will allow us to deepen our customer centric sales offering. We are thrilled to have him onboard!” states Svanbäck.

 Matt Fodor added: “It is my privilege to join The Solubility Company and work with this incredibly talented team. The SPA® technology is remarkable in many ways and has disrupted the conventional wisdom of what is possible in early pharmaceutical development.”

About The Solubility Company:


The Solubility Company is a contract research organization, focusing on early-stage solubility data generation, based on its proprietary image-based SPA® (Single Particle Analysis) technology. SPA® brings the benefit of microscopic sample consumption combined with speed and accuracy to the benefit of pharmaceutical research and development efforts. The Solubility Company’s service laboratories, located in Helsinki, Finland, and Quakertown, Pennsylvania, serve drug developers globally.


More information:


The Solubility Company:


Sami Svanbäck, CEO


[email protected]

Recent Posts